Ustekinumab for Resistant Pediatric Crohn Disease

J Pediatr Gastroenterol Nutr. 2016 Apr;62(4):e34-5. doi: 10.1097/MPG.0000000000000503.
No abstract available

Publication types

  • Case Reports

MeSH terms

  • Anti-Inflammatory Agents, Non-Steroidal / administration & dosage
  • Anti-Inflammatory Agents, Non-Steroidal / adverse effects
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Child
  • Crohn Disease / drug therapy*
  • Crohn Disease / physiopathology
  • Drug Administration Schedule
  • Drug Monitoring
  • Drug Resistance, Multiple*
  • Gastrointestinal Agents / administration & dosage
  • Gastrointestinal Agents / adverse effects
  • Gastrointestinal Agents / therapeutic use*
  • Growth Disorders / etiology
  • Growth Disorders / prevention & control
  • Humans
  • Immunosuppressive Agents / therapeutic use
  • Induction Chemotherapy* / adverse effects
  • Injections, Subcutaneous
  • Maintenance Chemotherapy
  • Male
  • Mercaptopurine / analogs & derivatives
  • Mercaptopurine / therapeutic use
  • Remission Induction
  • Ustekinumab / administration & dosage
  • Ustekinumab / adverse effects
  • Ustekinumab / therapeutic use*

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Gastrointestinal Agents
  • Immunosuppressive Agents
  • azathiopurine
  • Mercaptopurine
  • Ustekinumab

Supplementary concepts

  • Pediatric Crohn's disease